The correction refers to the missing information in the previous press release to note the auditor's remark, which is stated below.
The Annual General Meeting for the financial year 2023-05-01-2024-04-30 was held on 31 October 2024 despite the fact that the annual report with the signed audit report was not available to the Annual General Meeting. This is contrary to Chapter 7, Section 10 of the Companies Act.
During the financial year, the company, in violation of the Tax Procedure Act, did not pay the withheld tax, social security contributions or value-added tax on time.
The annual report is available on the company's website: https://phiab.com/annual-report/2024-25/
This disclosure contains information that Phase Holographic is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on [Date and time is inserted automatically].
For additional information, please contact:
Patrik Eschricht, CEO
E-mail: ir@phiab.com
Web: www.phiab.com - Live cell imaging & analysis
About PHI
Phase Holographic Imaging (PHI) is a medical technology company that develops and markets its non-invasive time-lapse imaging instruments for long-term quantitative analysis of living cells. The foundation of PHI's current commercial HoloMonitor® products is Quantitative Phase Imaging (QPI) technology - an innovative approach to cell quality evaluation. QPI offers detailed analysis of cell characteristics without harming the cells, avoiding the limitations of traditional measurement methods. PHI is actively focusing on business development to expand from pre-clinical research to the clinical market and the emerging regenerative medicine field. PHI envisions transforming live cell analysis and establishing QPI as a standard for cell quality control, making future cell therapies safe, affordable, and accessible for patients. PHI is based in Lund, Sweden, Boston, MA and Winston-Salem, NC.